Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China
This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2400081873.
Authors
- Dekui Zhang (ORCID: https://orcid.org/0000-0002-1392-7927)
- Benxin Xie (ORCID: https://orcid.org/0009-0003-2830-0371)
- Nian Xie (ORCID: https://orcid.org/0000-0001-7762-4493)
- Liping Gao (ORCID: https://orcid.org/0000-0001-8674-0234)
- Xinglan Chen (ORCID: https://orcid.org/0009-0000-1546-4527)
- Lihong Yang (ORCID: https://orcid.org/0000-0001-7581-1324)
- Yi Yu (ORCID: https://orcid.org/0000-0002-4891-451X)
- Ronghua Wu
- Jinxia Yang (ORCID: https://orcid.org/0009-0005-7685-8681)
- Yuanyuan Wang (ORCID: https://orcid.org/0009-0005-8449-3635)
- Yuehan Dong (ORCID: https://orcid.org/0009-0007-1519-9293)
- Hong Fan (ORCID: https://orcid.org/0009-0003-9768-2465)
- Xiuhong Zhang
Institutions
- Lanzhou University Second Hospital (CN)
- The People's Hospital of LinXia (CN)
- The First People's Hospital of Guiyang (CN)
- Pingliang People's Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1177/17562848251391276
- Citations
- 1
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01